伴腮腺转移的头颈部皮肤鳞状细胞癌的颈部管理
该回顾性研究纳入134例伴腮腺转移的头颈部皮肤鳞状细胞癌患者,比较观察、选择性颈清扫(END)和选择性颈照射(ENI)的肿瘤学结局与生活质量。Cox模型显示END和ENI较观察均改善区域控制(HR 0.27和0.34)和总生存(HR 0.22和0.30);腮腺阳性淋巴结≥3枚时END优于ENI;END与ENI生活质量12个维度可比。结论:不推荐观察,END为首选,ENI为替代方案。
要点
- 伴腮腺转移的头颈部皮肤鳞状细胞癌不推荐仅观察颈部。
- END和ENI较观察均改善区域控制与总生存,END为首选。
- 腮腺阳性淋巴结≥3枚时,END的区域控制和总生存显著优于ENI。
核心结论
- 在伴腮腺转移的头颈部皮肤鳞状细胞癌的颈部管理中,不推荐观察;END为首选方案,ENI为不损害生存或生活质量的替代方法,但腮腺转移淋巴结≥3枚的病例除外。
研究设计与样本
- 回顾性纳入伴腮腺转移的头颈部皮肤鳞状细胞癌患者,共134例。
- 采用Cox比例风险模型分析观察、END和ENI对区域控制和总生存的影响,以风险比(HR)及95%置信区间(CI)呈现。
- 使用华盛顿大学生活质量问卷评估接受END或ENI患者的生活质量。
主要发现
- 区域控制的Cox模型中,END较观察的HR为0.27(95% CI:0.15-0.69),ENI较观察的HR为0.34(95% CI:0.18-0.86)。
- 总生存的Cox模型中,END优于观察(p=0.001,HR:0.22,95% CI:0.10-0.72),ENI优于观察(p=0.006,HR:0.30,95% CI:0.17-0.83)。
- 腮腺阳性淋巴结≥3枚的患者中,END较ENI的区域控制显著更优(p<0.001),总生存显著更优(p=0.001)。
- END组与ENI组在华盛顿大学生活质量问卷全部12个维度上可比。
关键数值与推荐
- 区域控制:END较观察HR 0.27(95% CI:0.15-0.69),ENI较观察HR 0.34(95% CI:0.18-0.86)。
- 总生存:END较观察p=0.001,HR 0.22(95% CI:0.10-0.72);ENI较观察p=0.006,HR 0.30(95% CI:0.17-0.83)。
- 腮腺阳性淋巴结≥3枚:END较ENI区域控制p<0.001,总生存p=0.001。
- 生活质量:END组与ENI组在华盛顿大学生活质量问卷全部12个维度上可比。
临床怎么用
- 作者认为,伴腮腺转移的头颈部皮肤鳞状细胞癌的颈部管理不推荐观察。
- 作者认为,END为首选方案,ENI为不损害生存或生活质量的替代方法。
- 作者指出,腮腺转移淋巴结≥3枚的病例除外(即END优于ENI)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective is to assess the oncologic outcomes of observation, elective neck dissection (END), and elective neck irradiation (ENI) in the neck management of head and neck cutaneous squamous cell carcinoma (HNcSCC) with parotid metastasis (P+) and to evaluate the quality of life (QoL) of patients who received END or ENI. METHODS: Patients with P+ HNcSCC were retrospectively enrolled. The impact of observation, END, and ENI on regional control (RC) and overall survival (OS) was analyzed using Cox proportional hazards model with presentation via hazard ratio (HR) with a 95% confidence interval (CI). QoL was evaluated using the University of Washington Quality of Life questionnaire. RESULTS: A total of 134 patients were included in our analysis. In the Cox model for RC, both END and ENI had decreased HRs of 0.27 (95% CI: 0.15-0.69) and 0.34 (95% CI: 0.18-0.86), respectively, in comparison with observation. In the Cox model for OS, both END (p = 0.001, HR: 0.22, 95% CI: 0.10-0.72) and ENI (p = 0.006, HR: 0.30, 95% CI: 0.17-0.83) were superior to observation. In patients with three or more positive parotid lymph nodes, END resulted in significantly better RC (p < 0.001) and OS (p = 0.001) compared with ENI. The two groups were found to be comparable in all 12 domains of the University of Washington Quality of Life questionnaire. CONCLUSION: In the neck management of P+ HNcSCC, observation is not recommended. END is the preferred option, but ENI is an alternative method without compromise to survival or QoL, except in cases with three or more metastatic parotid lymph nodes.
引用
- Fang Q, Yuan J, Zhang X, et al. Neck management in cutaneous squamous cell carcinoma with parotid metastasis. Head Neck. 2024. PMID: 38334480. doi:10.1002/hed.27676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。